Nektar Therapeutics (NKTR) Misses Q2 EPS by 258c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $74.38 +2.25%
EPS Growth %: -215.7%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
VIVO, PMCB, PLCE, More
EPS Growth %: -215.7%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($2.78), $2.58 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $11.17 million versus the consensus estimate of $9.74 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Subaru, other Japan suppliers to team on delivery as Boeing raises output - Nikkei
- Lands' End (LE) Tops Q2 EPS by 1c
- Daiwa Securities Upgrades Hutchison China MediTech Ltd. (HCM) to Buy (1)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
